Download from app store
We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Published in Oncology

Journal Scan / Research · August 09, 2013

Randomized, Phase II, Placebo-Controlled, Double-Blind Study With and Without Enzastaurin in Combination With Paclitaxel and Carboplatin As First-Line Treatment Followed by Maintenance Treatment in Advanced Ovarian Cancer.

Journal of Clinical Oncology

 

Additional Info

Journal of Clinical Oncology
Randomized, Phase II, Placebo-Controlled, Double-Blind Study With and Without Enzastaurin in Combination With Paclitaxel and Carboplatin As First-Line Treatment Followed by Maintenance Treatment in Advanced Ovarian Cancer.
J. Clin. Oncol 2013 Jul 29;[EPub Ahead of Print], IB Vergote, R Chekerov, F Amant, P Harter, A Casado, J Emerich, T Bauknecht, K Mansouri, SP Myrand, TS Nguyen, P Shi, J Sehouli

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading